Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials
Open forum infectious diseases
; 9(8), 2022.
Article
in English
| EuropePMC | ID: covidwho-1990178
ABSTRACT
Host-directed therapeutics targeting immune dysregulation are considered the most promising approach to address the unmet clinical need for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). To better understand the current clinical study landscape and gaps in treating hospitalized patients with severe or critical COVID-19, we identified COVID-19 trials developing host-directed therapies registered at ClinicalTrials.gov and discussed the factors contributing to the success vs failure of these studies. We have learned, instead of the one-size-fits-all approach, future clinical trials evaluating a targeted immunomodulatory agent in heterogeneous patients with ALI/ARDS due to COVID-19 or other infectious diseases can use immune-based biomarkers in addition to clinical and demographic characteristics to improve patient stratification and inform clinical decision-making. Identifying distinct patient subgroups based on immune profiles across the disease trajectory, regardless of the causative pathogen, may accelerate evaluating host-directed therapeutics in trials of ALI/ARDS and related conditions (eg, sepsis).
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Language:
English
Journal:
Open forum infectious diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS